MXCT MaxCyte, Inc.
$1.54▲ +1.99%
Healthcare
Other
After hours
$1.57▲ +1.95%
Oct 27, 5:32 PM ET
Volume 1.58M
Avg Volume (10D) 2.45M
Key Metrics & Fundamentals
Market Cap
$158.94M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.64 - 1.81
% vs 50 MA
24.50%
% vs 200 MA
45.64%
RSI-14
72.1
MACD Histogram
+0.0400
Beta (1Y vs SPY)
1.45
Free Cash Flow
-$4.72M
Gross Rev
$7.27M
Gross Profit
$5.60M
EBITDA
-$9.03M
COGS
$1.68M
Operating Exp
$15.83M
Operating Income
-$10.23M
EBIT
-$10.23M
Pretax Income
-$8.87M
Net Income
-$8.87M
EPS (Diluted)
-0.08
Price & Volume History
Loading chart…
Recent News
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
GlobeNewswire · Oct 14, 2026 8:05 AM ET
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Zacks · Oct 6, 2026 4:07 AM ET
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
GlobeNewswire · Sep 23, 2026 8:05 AM ET
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 11, 2026 4:30 PM ET
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 19, 2026 7:01 PM ET
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
GlobeNewswire · Aug 19, 2026 8:05 AM ET
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...
GuruFocus.com · Aug 13, 2026 1:03 AM ET
MaxCyte, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 12, 2026 9:50 PM ET
MaxCyte Q2 Earnings Call Highlights
MarketBeat · Aug 12, 2026 9:04 PM ET
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 12, 2026 6:15 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See MXCT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.